Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
RayzeBio, Inc.
National Institutes of Health Clinical Center (CC)
RayzeBio, Inc.
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc.
Cedars-Sinai Medical Center
Fox Chase Cancer Center
Hospices Civils de Lyon
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Advanced Accelerator Applications
CHU de Quebec-Universite Laval
AC Camargo Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Roswell Park Cancer Institute
SCRI Development Innovations, LLC
University of Alabama at Birmingham
Radio Isotope Therapy of America
H. Lee Moffitt Cancer Center and Research Institute
British Columbia Cancer Agency
Ipsen
University of Chicago
University of Iowa
Novartis
University of Iowa
University of California, San Francisco
H. Lee Moffitt Cancer Center and Research Institute
University of California, San Francisco
Eli Lilly and Company
Novartis
Arbutus Biopharma Corporation
CHU de Reims
Western University, Canada
Dana-Farber Cancer Institute
Mateon Therapeutics
Vanderbilt-Ingram Cancer Center
Icahn School of Medicine at Mount Sinai
Stanford University
Novartis
Dana-Farber Cancer Institute
Columbia University
Vanderbilt-Ingram Cancer Center
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Dana-Farber Cancer Institute
Ochsner Health System
H. Lee Moffitt Cancer Center and Research Institute
Molecular Insight Pharmaceuticals, Inc.
Cylene Pharmaceuticals
Guangdong Provincial People's Hospital